Skip to main content

Table 1 Precision of endpoint estimates

From: The endTB observational study protocol: treatment of MDR-TB with bedaquiline or delamanid containing regimens

Endpoint Proportion

95% CI

0

[0, 0.0015]a

0.05

[0.04, 0.06]

0.10

[0.09, 0.11]

0.20

[0.18, 0.22]

0.30

[0.28, 0.32]

0.40

[0.38, 0.42]

0.50

[0.48, 0.52]

0.60

[0.58, 0.62]

0.70

[0.68, 0.72]

0.80

[0.78, 0.82]

0.90

[0.89, 0.91]

  1. aExact 95 CI
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us